These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19902140)

  • 41. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma.
    Imsumran A; Adachi Y; Yamamoto H; Li R; Wang Y; Min Y; Piao W; Nosho K; Arimura Y; Shinomura Y; Hosokawa M; Lee CT; Carbone DP; Imai K
    Carcinogenesis; 2007 May; 28(5):947-56. PubMed ID: 17183068
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.
    Ulanet DB; Ludwig DL; Kahn CR; Hanahan D
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10791-8. PubMed ID: 20457905
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
    Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors.
    Denley A; Carroll JM; Brierley GV; Cosgrove L; Wallace J; Forbes B; Roberts CT
    Mol Cell Biol; 2007 May; 27(10):3569-77. PubMed ID: 17325037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.
    Friedbichler K; Hofmann MH; Kroez M; Ostermann E; Lamche HR; Koessl C; Borges E; Pollak MN; Adolf G; Adam PJ
    Mol Cancer Ther; 2014 Feb; 13(2):399-409. PubMed ID: 24296829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved.
    Pandini G; Frasca F; Mineo R; Sciacca L; Vigneri R; Belfiore A
    J Biol Chem; 2002 Oct; 277(42):39684-95. PubMed ID: 12138094
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
    Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
    BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Picropodophyllin inhibits tumor growth of human nasopharyngeal carcinoma in a mouse model.
    Yin SC; Guo W; Tao ZZ
    Biochem Biophys Res Commun; 2013 Sep; 439(1):1-5. PubMed ID: 23973483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
    Cao L; Yu Y; Darko I; Currier D; Mayeenuddin LH; Wan X; Khanna C; Helman LJ
    Cancer Res; 2008 Oct; 68(19):8039-48. PubMed ID: 18829562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tissue distribution and cancer growth inhibition of magnetic lipoplex-delivered type 1 insulin-like growth factor receptor shRNA in nude mice.
    Kong M; Li X; Wang C; Ding C; Dong A; Duan Q; Shen Z
    Acta Biochim Biophys Sin (Shanghai); 2012 Jul; 44(7):591-6. PubMed ID: 22626974
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
    Emanuel SL; Engle LJ; Chao G; Zhu RR; Cao C; Lin Z; Yamniuk AP; Hosbach J; Brown J; Fitzpatrick E; Gokemeijer J; Morin P; Morse BA; Carvajal IM; Fabrizio D; Wright MC; Das Gupta R; Gosselin M; Cataldo D; Ryseck RP; Doyle ML; Wong TW; Camphausen RT; Cload ST; Marsh HN; Gottardis MM; Furfine ES
    MAbs; 2011; 3(1):38-48. PubMed ID: 21099371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers.
    Sabbatini P; Korenchuk S; Rowand JL; Groy A; Liu Q; Leperi D; Atkins C; Dumble M; Yang J; Anderson K; Kruger RG; Gontarek RR; Maksimchuk KR; Suravajjala S; Lapierre RR; Shotwell JB; Wilson JW; Chamberlain SD; Rabindran SK; Kumar R
    Mol Cancer Ther; 2009 Oct; 8(10):2811-20. PubMed ID: 19825801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative.
    Chakravarti B; Siddiqui JA; Dwivedi SK; Deshpande S; Samanta K; Bhatta RS; Panda G; Prabhakar YS; Konwar R; Sanyal S; Chattopadhyay N
    Mol Cell Endocrinol; 2011 May; 338(1-2):68-78. PubMed ID: 21457754
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
    Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
    Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Combinational effects of K-ras and IGF-IR antisense oligodeoxynucleotide on proliferation and apoptosis of human pancreatic cancer Patu8988 cells].
    Shen YM; Yang XC; Zhang MH; Shen JK; Sun YH
    Ai Zheng; 2008 May; 27(5):496-504. PubMed ID: 18479599
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
    Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ
    Mol Cancer Ther; 2009 Aug; 8(8):2122-30. PubMed ID: 19638450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
    Carboni JM; Wittman M; Yang Z; Lee F; Greer A; Hurlburt W; Hillerman S; Cao C; Cantor GH; Dell-John J; Chen C; Discenza L; Menard K; Li A; Trainor G; Vyas D; Kramer R; Attar RM; Gottardis MM
    Mol Cancer Ther; 2009 Dec; 8(12):3341-9. PubMed ID: 19996272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced therapeutic effects for human pancreatic cancer by application K-ras and IGF-IR antisense oligodeoxynucleotides.
    Shen YM; Yang XC; Yang C; Shen JK
    World J Gastroenterol; 2008 Sep; 14(33):5176-85. PubMed ID: 18777594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
    Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
    Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.